These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 15125705

  • 1. Endocrine complications of high-dose therapy with stem cell transplantation.
    Sanders JE.
    Pediatr Transplant; 2004 Jun; 8 Suppl 5():39-50. PubMed ID: 15125705
    [Abstract] [Full Text] [Related]

  • 2. Growth and development after hematopoietic cell transplant in children.
    Sanders JE.
    Bone Marrow Transplant; 2008 Jan; 41(2):223-7. PubMed ID: 17922039
    [Abstract] [Full Text] [Related]

  • 3. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood.
    Bakker B, Oostdijk W, Bresters D, Walenkamp MJ, Vossen JM, Wit JM.
    Bone Marrow Transplant; 2004 May; 33(10):1049-56. PubMed ID: 15048143
    [Abstract] [Full Text] [Related]

  • 4. Long term effects and quality of life in children and adults after marrow transplantation.
    Sanders J, Sullivan K, Witherspoon R, Doney K, Anasetti C, Beatty P, Petersen FB.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():27-9. PubMed ID: 2697434
    [Abstract] [Full Text] [Related]

  • 5. Late effects in children after bone marrow transplantation: a review.
    Locatelli F, Giorgiani G, Pession A, Bozzola M.
    Haematologica; 1993 Dec; 78(5):319-28. PubMed ID: 8314162
    [Abstract] [Full Text] [Related]

  • 6. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
    Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, Nance AG, Tilden AB, Carabasi MH.
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
    [Abstract] [Full Text] [Related]

  • 7. [Analysis of some risk factors for abnormal growth velocity in children treated with haematopoetic stem cell transplantation].
    Wójcik D, Barg E, Niedzielska E, Doroszko A, Kałwak K, Pietras W.
    Med Wieku Rozwoj; 2006 Jul; 10(3 Pt 1):841-8. PubMed ID: 17317915
    [Abstract] [Full Text] [Related]

  • 8. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
    Yoshimi A, Nannya Y, Sakata-Yanagimoto M, Oshima K, Takahashi T, Kanda Y, Motokura T, Chiba S, Kurokawa M.
    Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
    [Abstract] [Full Text] [Related]

  • 9. Endocrinological late complications after hematopoietic SCT in children.
    Cohen A, Békássy AN, Gaiero A, Faraci M, Zecca S, Tichelli A, Dini G, EBMT Paediatric and Late Effects Working Parties.
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S43-8. PubMed ID: 18545244
    [Abstract] [Full Text] [Related]

  • 10. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
    Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E.
    Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
    [Abstract] [Full Text] [Related]

  • 11. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 12. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP.
    Biol Blood Marrow Transplant; 2004 Sep 20; 10(9):614-23. PubMed ID: 15319773
    [Abstract] [Full Text] [Related]

  • 13. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB.
    Biol Blood Marrow Transplant; 2009 Nov 20; 15(11):1447-54. PubMed ID: 19822305
    [Abstract] [Full Text] [Related]

  • 14. Endocrine complications of hematopoietic stem cell transplantation.
    Chemaitilly W, Sklar CA.
    Endocrinol Metab Clin North Am; 2007 Dec 20; 36(4):983-98; ix. PubMed ID: 17983932
    [Abstract] [Full Text] [Related]

  • 15. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
    Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W.
    Bone Marrow Transplant; 2009 Aug 20; 44(3):157-61. PubMed ID: 19204716
    [Abstract] [Full Text] [Related]

  • 16. [Alterations in coagulation in patients during transplant conditioning regimen before allogeneic hematopoietic stem cell transplantation].
    Jiang Q, Huang XJ, Liu KY, Chen H, Chen YH, Gao ZY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar 20; 27(3):173-7. PubMed ID: 16792919
    [Abstract] [Full Text] [Related]

  • 17. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens.
    Gassas A, Sung L, Saunders EF, Doyle JJ.
    Bone Marrow Transplant; 2006 Dec 20; 38(11):739-43. PubMed ID: 17013424
    [Abstract] [Full Text] [Related]

  • 18. Disturbance of pubertal development after cancer treatment.
    Müller J.
    Best Pract Res Clin Endocrinol Metab; 2002 Mar 20; 16(1):91-103. PubMed ID: 11987901
    [Abstract] [Full Text] [Related]

  • 19. Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases.
    Somali M, Mpatakoias V, Avramides A, Sakellari I, Kaloyannidis P, Smias C, Anagnostopoulos A, Kourtis A, Rousso D, Panidis D, Vagenakis A.
    Gynecol Endocrinol; 2005 Jul 20; 21(1):18-26. PubMed ID: 16048797
    [Abstract] [Full Text] [Related]

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 20; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.